Ancor Holdings: Due Diligence, Management Control and the Alliance Settlement

The Ancor Holdings Alliance kickback settlement required Ancor to pay $1,780,349 to the federal government and $64,369 to state Medicaid programs over allegations that it allowed EEG referral kickbacks to continue after learning about them during due diligence. The investor’s alleged knowledge before the deal, and its management role afterward, put it inside the case. If you saw what an investment team learned about a referral arrangement and what management did next, this is the part of the story you may recognize.

Ancor Holdings LP is a Texas private investment company. In its July 21, 2021 announcement, the Justice Department described a separate settlement obligation for Ancor alongside the payment by Alliance Family of Companies, the EEG testing business it invested in.

Free EEG Reports Gave Referrals a Payoff

Alliance provided ambulatory electroencephalography testing for patients referred by physicians and other health care providers to diagnose neurological conditions. The Justice Department alleged that Alliance induced physicians to order its tests by supplying free EEG interpretation reports. Those reports allegedly enabled primary-care physicians who were not neurologists to bill the government as if they had interpreted the tests themselves.

The benefit in this alleged physician kickback arrangement was a report the referring physician could turn into a bill. We see the absurdity: under the alleged arrangement, taxpayers paid the referring doctor for an interpretation someone else supplied for free.

A whistleblower complaint described how the report’s labels allegedly made that possible. It alleged that the specialist’s interpretation appeared under one label while the referring provider signed beneath another:

That allegation gives a billing employee something concrete to recognize: the work, the report heading and the signature could tell different stories about who interpreted the test. The government separately alleged that Alliance used an inaccurate EEG billing code to obtain higher reimbursement and charged for specialized digital analysis it did not perform.

The same complaint alleged that a neurologist was expected to refer his own patients to Alliance to be eligible to interpret its EEGs. That allegation puts the reading assignment itself inside the referral exchange: the specialist supplying interpretations could also be a source of testing orders.

Why Ancor’s Due Diligence Mattered

The government alleged that Ancor learned about the kickbacks during due diligence before investing in Alliance. It then allegedly caused false claims by allowing the conduct to continue after entering an agreement to manage Alliance. That sequence is the substance of this private equity fraud allegation: information reached the investor, management followed, and the referral arrangement allegedly kept producing claims.

Ancor’s alleged role makes the management agreement and operating authority central to the story. In an acquired healthcare business, the people who own the shares and the people who control billing or staffing can be different.

The chapter Implementing a Physician Practice Compliance Program, published by Jones and Bartlett Publishers in 2011, identifies a problem employees may recognize. It distinguishes responsibility for a task from the authority to act, and puts the mismatch plainly:

The government’s account connects what the investor learned to the management role it later assumed. An insider may know who received the finding, who could act on it and what happened to the referral arrangement afterward. A person responsible for flagging a problem and a person empowered to stop it may occupy different offices.

Alliance’s Obligations and the Whistleblower Award

Alliance agreed to pay $13,022,356 to the federal government and $477,643 to state Medicaid programs. The investor’s own settlement bill was a fraction of the testing company’s, for allegedly allowing the kickbacks to continue.

The case concerned programs beyond Medicare and Medicaid: the announcement also described protecting TRICARE and the Federal Employees Health Benefits Program. Alliance entered a five-year Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General.

The resolution covered six False Claims Act qui tam cases in the Southern District of Texas. The announcement allocated nearly $3 million of the federal settlement proceeds to two whistleblowers, together with a share of qualifying additional recoveries. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

What Management Knew and What Kept Getting Billed

An insider may see the warning, the management response or the billing that continued after it. In an allegation like Ancor’s, we connect those parts: the diligence finding, the authority assigned by the management agreement and the referral arrangements that continued to generate government claims. The dates and recipients of a finding matter because the government’s allegation concerns knowledge followed by continued conduct.

On the testing side, the complaint’s description points to the interpretation report, its labels and the referring provider’s signature. On the management side, the questions concern who learned about the arrangement and who had the authority to change it. Connecting those records is how we examine evidence of physician billing fraud with someone who knows the business from within.

In the Justice Department’s Oliver Street Dermatology Management settlement, the government alleged that the company increased or offered to increase practice purchase prices in exchange for referrals after acquisition. The alleged benefit there was embedded in the purchase price. In Ancor’s case, the government focused on what the investor allegedly learned before investing and allowed to continue through management afterward.

Those accounts give an employee in acquisitions, finance or practice operations a concrete place in the story. Knowledge of the purchase terms or the response to a diligence finding can explain a referral arrangement that a claim alone does not reveal. Our work with you connects the business decision to the service, the bill and the government money at stake.

You Saw the Decisions Behind the Deal

If you know what diligence uncovered or why a referral arrangement continued after an investment, talk with our whistleblower experts about what you saw. We work beside you to build your strongest whistleblower case around those decisions and bring in healthcare fraud whistleblower lawyers who understand investor control and physician referral payments. You bring the view from inside the business, and we bring the expertise to carry it through the case with you.